Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9632329 | 0.95 | FDPS (0.39) | FDPSSMPD1GGPS1KDM4ETP53 | |
| SCHEMBL10357106 | 0.93 | GGPS1 (0.42) | FDPSSMPD1GGPS1KDM4ETP53 | |
| SCHEMBL9633798 | 0.93 | GGPS1 (0.42) | FDPSSMPD1GGPS1KDM4ETP53 | |
| SCHEMBL10357811 | 0.89 | FDPS (0.33) | FDPS | |
| SCHEMBL11636720 | 0.84 | FDPS (0.39) | FDPSSMPD1GGPS1KDM4ETP53 | |
| SCHEMBL16841368 | 0.84 | FDPS (0.35) | FDPSSMPD1GGPS1KDM4ETP53 | |
| SCHEMBL7952899 | 0.84 | ALDH1A1 (0.36) | TSHRCYP4F2CYP4A11 | |
| SCHEMBL10994874 | 0.83 | LPAR1 (0.36) | FDPSFAAH | |
| SCHEMBL11298075 | 0.83 | LPAR1 (0.36) | FDPSFAAH | |
| SCHEMBL10923954 | 0.83 | FDPS (0.34) | FDPSSMPD1GGPS1CYP3A4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | MYOMETRICS, LLC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2019-03-28 | — | — | US | disclosed |
| US-4001300-A | ANTIULCER, DECONGESTANT, LABOR INDUCER, WOUND HEALER | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3987081-A | ALKYL DERIVATIVES OF PROSTANOIC ACIDS AND PREPARATION THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3987072-A | CIS-4,5-Didehydro-15- or 16-alkylated 11-deoxy-PGE1 analogs | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3987085-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3969396-A | 8β, 11β, 12α-PGE2 compounds | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3959263-A | Prostaglandin intermediate | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
| US-3954833-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| US-3953466-A | TETRAZOYL DERIVATIVES OF PROSTAGLANDINS | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
| US-3933889-A | 4,5-Cis-didehydro-PGF1.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
| US-20190144435-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FDPS 225/4885SMPD1 1712/4885GGPS1 429/4885 |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | FDPS 354/4885SMPD1 1290/4885GGPS1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.